PHASTAR announced that it has entered into a technology partnership with Medidata Solutions, Inc. PHASTAR will deploy several solutions from the Medidata Rave Clinical Cloud including Rave EDC, Coder, eCOA, and RTSM.
The adoption of the Medidata Rave Clinical Cloud comes as PHASTAR continues to grow its market share in data services. PHASTAR has expanded its Data Operations teams in Kenya and the UK to provide professional services, and, with the opening of its second U.S. office in Boston, its partnership with Medidata will further power its U.S. expansion.
PHASTAR understands that Medidata is an innovative partner that provides technology for servicing data studies, along with transformative and collaborative solutions to help PHASTAR support emerging techniques.
“We are excited to partner with PHASTAR in its mission to support the pharmaceutical and biotech sector in safely bringing new therapies and medical devices to patients,” said Glen de Vries, co-founder and president, Medidata. “Our unified platform will enable PHASTAR to design and conduct complex clinical trials, and turn large volumes of data into insights."
Andrew MacGarvey, Managing Director, PHASTAR, said, “I am pleased to expand our offering following the addition of the Medidata platform to our technology solutions. Our Data Operations team deliver excellent services across the world and Medidata will allow the team to service projects more efficiently as they work within the unified platform. Our new Data Sciences group is developing tools and techniques to help our customers maximise the data they collect. Medidata understand that the types of data collected during clinical trials are changing and the amount of data underpinning clinical research is increasing extremely quickly. We hope to work closely with their team as our customer needs evolve over the coming years.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.